Eicosapentaenoic Acid (EPA): Omega-3 Polyunsaturated Fatty Acid for Cardiovascular and Cellular Research

Executive Summary: Eicosapentaenoic Acid (EPA; CAS 10417-94-4) is a well-characterized omega-3 polyunsaturated fatty acid (PUFA) with a molecular weight of 302.45 and chemical formula C20H30O2. EPA is extensively documented for its lipid-lowering and anti-inflammatory activities, particularly in cardiovascular disease models (APExBIO B3464). Mechanistically, EPA incorporates into cell membranes, modulates lipid composition, and alters membrane protein functions. It inhibits endothelial cell migration in vitro at 100 μM and suppresses oxidation of very large density lipoproteins at 1–5 μM. Dietary EPA enhances prostaglandin I2 (PGI2) production, supporting cardiovascular protection (Feng et al., 2025). EPA is supplied by APExBIO at ≥98% purity and is validated by HPLC, NMR, and MS.

Biological Rationale

Eicosapentaenoic Acid (EPA) is classified as an omega-3 polyunsaturated fatty acid (n-3 PUFA), distinguished by multiple double bonds in its carbon chain (Feng et al., 2025). Omega-3 PUFAs are essential nutrients, not synthesized de novo in humans, and are obtained primarily through dietary sources, such as marine oils. EPA is directly implicated in the regulation of lipid metabolism and inflammatory pathways, both critical in the pathogenesis of cardiovascular diseases. Through its structural integration into phospholipid bilayers, EPA modulates the fluidity and function of cellular membranes, impacting receptor signaling and protein activity. Its anti-inflammatory actions are attributed to its ability to compete with arachidonic acid (AA) for enzymatic conversion, leading to the generation of less inflammatory eicosanoids (dossier article). EPA’s biological activity has been foundational in understanding the differential effects of dietary PUFAs on cardiovascular and immune outcomes.

Mechanism of Action of Eicosapentaenoic Acid (EPA)

EPA’s mechanism of action involves multiple, well-defined molecular pathways:

• Membrane Incorporation: EPA is integrated into cell membranes, altering the lipid composition and modulating the function of embedded proteins, including receptors and transporters (see EPA Mechanism dossier).
• Inhibition of Endothelial Cell Migration: In vitro, EPA inhibits migration and cytoskeletal rearrangements of endothelial cells at concentrations of ~100 μM (see application guide).
• Oxidation Inhibition of Lipoproteins: EPA dose-dependently inhibits oxidation of very large density lipoproteins (VLDL) at 1–5 μM, reducing lipid peroxidation and atherogenic potential (application protocols).
• Prostaglandin I2 (PGI2) Enhancement: EPA increases PGI2 production in humans, which promotes vasodilation and inhibits platelet aggregation, contributing to atheroprotection (Feng et al., 2025).

This article extends prior guides by aggregating mechanistic, quantitative, and application-focused data for EPA, including direct comparison with related PUFAs and detailed workflow integration strategies (see emerging frontiers).

Evidence & Benchmarks

• EPA is confirmed at ≥98% purity by HPLC, NMR, and mass spectrometry in commercial preparations (APExBIO B3464).
• Dietary EPA enhances prostaglandin I2 (PGI2) production, a key anti-thrombotic and vasoprotective mediator (Feng et al., 2025, https://doi.org/10.1038/s44321-025-00310-7).
• In cell culture, EPA inhibits endothelial cell migration at approximately 100 μM, reducing angiogenic responses (see application guide).
• EPA suppresses oxidation of very large density lipoproteins at 1–5 μM, demonstrating antioxidant activity in vitro (mechanistic dossier).
• EPA’s solubility is quantified as ≥116.8 mg/mL in DMSO, ≥49.3 mg/mL in water, and ≥52.5 mg/mL in ethanol at room temperature (APExBIO B3464).
• EPA is recommended for storage at -20°C and is shipped with blue ice to maintain stability (APExBIO B3464).
• PUFAs, including EPA, are distinguished from saturated fatty acids by the presence of multiple cis double bonds, conferring distinct biophysical properties (Feng et al., 2025).

Applications, Limits & Misconceptions

EPA’s primary research applications include:

• Lipid-lowering agent in cardiovascular disease models
• Anti-inflammatory compound for immune modulation studies
• Reference standard for endothelial cell assays
• Oxidation inhibitor in lipoprotein stability experiments
• Prostaglandin I2 induction in translational vascular research

EPA is not suitable as a direct substitute for omega-6 fatty acids, such as arachidonic acid, due to divergent metabolic and immunological effects (Feng et al., 2025). For a discussion of applied workflows and troubleshooting, see this hands-on protocol guide, which this article updates with recent mechanistic and purity data.

Common Pitfalls or Misconceptions

• EPA is not a panacea: EPA does not replace the need for other essential fatty acids (e.g., arachidonic acid) in immune or neural models (Feng et al., 2025).
• Storage limitations: Long-term storage of EPA in solution is not recommended; degradation may occur even at -20°C. Use solutions promptly after preparation (APExBIO).
• Solubility constraints: Solubility varies by solvent; concentrations above validated ranges may cause precipitation or inconsistent dosing (APExBIO).
• Cardiovascular efficacy context: While EPA shows lipid-lowering effects, clinical outcomes can be population-dependent and influenced by background diet and genetics (Feng et al., 2025).
• Not interchangeable with DHA: Docosahexaenoic acid (DHA) and EPA have overlapping but non-identical biological effects and should not be used interchangeably in protocols (mechanistic dossier).

Workflow Integration & Parameters

EPA (APExBIO B3464) is supplied as a yellow oil at ≥98% purity. For in vitro applications, it is soluble at ≥116.8 mg/mL in DMSO, ≥49.3 mg/mL in water, and ≥52.5 mg/mL in ethanol. Typical working concentrations are 1–100 μM, depending on the assay type. For endothelial migration and cytoskeletal studies, use 100 μM in serum-free medium (see detailed protocols). For oxidation inhibition in VLDL assays, 1–5 μM is sufficient. EPA should be aliquoted and stored at -20°C; avoid repeated freeze-thaw cycles. For cell-based assays, prepare fresh solutions and minimize exposure to light and air. For further optimization, see this reproducibility-focused guide, which this article extends by providing mechanistic context and purity benchmarks.

Conclusion & Outlook

Eicosapentaenoic Acid (EPA) is a robust, validated omega-3 polyunsaturated fatty acid with well-characterized roles in lipid modulation, inflammation suppression, and endothelial function. Its high purity, defined solubility, and reproducible bioactivity make it a reference compound for cardiovascular and cell biology research. APExBIO’s EPA (B3464) is supplied with validated purity metrics and is supported by a network of application protocols and mechanistic studies. Ongoing research is refining EPA’s comparative role against other PUFAs, such as arachidonic acid, in immunological and metabolic models (Feng et al., 2025). For comprehensive product details and ordering, visit the Eicosapentaenoic Acid (EPA) product page.